



APCI • 2024/25 Pfizer Vaccine Pricing

Revised 7/2/2024

CONTRACT PRICES, CONTRACT DISCOUNTS, AND REBATES

Product Category	Contract Discounts* or Contract Prices**			“3 for 3” Rebate
	Market Share TIER 1	Market Share TIER 2	Market Share TIER 3	
	0-59.99% Market Share	60.00-79.99% Market Share	> 80.00% Market Share	
Future Formulations of COMIRNATY DO NOT FREEZE	\$122.55 15% Returns	\$100.62 30% Returns	\$96.75 100% Returns	3%
Future Formulations of COVID-19 Vaccine - SDV	\$73.15 15% Returns	\$61.60 30% Returns	\$61.60 100% Returns	3%
Future Formulations of COVID-19 Vaccine - MDV	\$54.63 15% Returns	\$46.00 30% Returns	\$46.00 100% Returns	3%
ABRYSV0	\$280.25	\$241.90	\$233.05	3%
PREVNAR 20	\$247.77	\$247.77	\$239.95	3%
TRUMENBA	\$168.66	\$168.66	\$153.50	N/A
PENBRAYA	\$211.60	\$211.60	\$211.60	N/A

* Any rates listed with an asterisk (*) indicates a Contract Discount. All other rates are Contract Prices.

**For purposes of Contract Prices, Table 2 displays Contract Prices at the dose level. Pfizer shall load the Contract Price to the Pfizer Distributor at the package level per NDC for Customer purchasing.

**All APCI Members Qualify for
the Lowest Tier 3 Pricing!**

*If APCI purchases of these vaccines is at
Tier 3 > 80% total, members will earn an
additional 3% rebate.*



APCI • 2024/25 Pfizer Vaccine Pricing

Revised 7/2/2024

COVERED PRODUCT AND CONTRACT DISCOUNTS / REBATES
Effective July 1, 2024 - June 30, 2025

NDC	Covered Product Description	Product Category
00005-2000-02	Pevnar 20 0.5 ml 1x1 Prefilled Syringe	Pevnar 20
00005-2000-10	Pevnar 20 0.5 ml 1x10 Prefilled Syringe	
00069-0344-01	ABRYSVO Carton: 1 kit	ABRYSVO
00069-0344-05	ABRYSVO Carton: 5 kits	
00069-0100-10	TRUMENBA 0.5ML 1X5 PFS US Units	TRUMENBA
00005-0100-10	TRUMENBA 0.5ML 1X10 PFS US Units	
00069-0600-01	PENBRAYA, Carton: 1 kit	PENBRAYA
00069-0600-05	PENBRAYA, Carton: 5 kits	
00069-0600-10	PENBRAYA, Carton: 10 kits	
00069-2476-10	TBD - Future Formulations of COMIRNATY: Ages 12y and older, Ten (10) Single dose Glass, Prefilled syringes. DO NOT FREEZE inclusive of updated formulations and new presentations of existing Vaccines	Future Formulations of COMIRNATY - DO NOT FREEZE*
59267-4410-02	TBD - Future Formulations of Pfizer-BioNTech COVID-19 Vaccine: Ages 5y-11y, Ten (10) Single dose vials inclusive of updated formulations and new presentations of existing Vaccines	Future Formulations of Pfizer-BioNTech COVID-19 Vaccine SDV*
59267-4403-02	TBD - Future Formulations of Pfizer-BioNTech COVID-19 Vaccine: Ages 6m-4y, Ten (10) Multiple dose vials; 3-doses per vial inclusive of updated formulations and new presentations of existing Vaccines	Future Formulations of Pfizer-BioNTech COVID-19 Vaccine MDV*

** Inclusion of any COVID-19 vaccine in this Agreement is conditioned upon FDA approval or EUA authorization. If the product is not FDA approved or EUA authorized, any part of this Agreement relating to such product will terminate automatically. COVID-19 Vaccine NDCs and Covered Product Descriptions may be updated by Pfizer. Any updated or new COVID-19 Vaccine NDCs will be added by Pfizer via written notification, an amendment shall not be required.*

Emergency Use Authorization. Emergency uses of COVID-19 vaccines from BioNTech and Pfizer have not been approved or licensed by FDA, but have been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals aged 6 months of age and older. The emergency use of these products is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheets at www.cvdvaccine-us.com